NCT01237132已完成不适用
EAST-WEST HEPATOCELLULAR CARCINOMA STUDY GROUP
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 主要终点
- Overall survival of resected patients for HCC
研究概览
简要总结
The current treatment guidelines of hepatocellular carcinoma (HCC) of the American and European Associations for the Study of Liver Disease are based on the Barcelona-Clinic-Liver-Cancer classification (BCLC), which does not recommend surgery in patients with large, multinodular and macrovascular invasive disease. The aim of this study was to investigate the role of hepatic resection in a large retrospective multicentric cohort of patients resected for HCC regardless of the BCLC indications.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •clinical diagnosis of hepatocellular carcinoma
- •candidate to liver resection as a curative treatment
排除标准
- •uncertain diagnosis of hepatocellular carcinoma
- •uncertain follow-up data
结局指标
主要结局
Overall survival of resected patients for HCC
The primary endpoint of the study was the overall survival of patients resected for HCC in any stage of the BCLC classification.
次要结局
- Disease-free survival of resected patients for HCC
研究者
相似试验
已完成
2 期
GH, IGF-I and Somatostatin Analogues in Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT00495846Federico II University25
已完成
不适用
A New Conception About Individualized Treatment Allocation for HCCTransarterial ChemoembolizationResectionHCCNCT06008548Tang-Du Hospital4,991
进行中（未招募）
不适用
Treatment of advanced hepatocellular carcinoma (HCC) with portal vein thrombosis by hepatic intra-arterial injection of microspheres loaded with Yttrium-90 (Thera-Sphere) - RAD-09advanced hepatocellular carcinoma (HCC) with portal vein thrombosisMedDRA version: 9.1Level: LLTClassification code 10024662MedDRA version: 9.1Level: PTClassification code 10019713EUCTR2009-016475-29-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
进行中（未招募）
1 期
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)Hepatocellular Carcinoma (HCC)NCT06487559AbbVie3
招募中
2 期
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaNCT06109272AbbVie660